Yingqi Zhang

3.7k citations
127 papers · 2.8k indexed · 1 hit paper · h-index 28

Yingqi Zhang

125 papers receiving 2.7k citations

Hit Papers

Biomimetic Macrophage Membrane-Camouflaged Nanoparticles ...1062023202620242025255075100

Peers

Yingqi Zhang
Comparison fields: 5 of 126
  • Cancer Research 482
  • Immunology 425
  • Molecular Biology 1.3k
  • Organic Chemistry 517
  • Oncology 471
Replace Jingxuan Pan with:
Jingxuan Pan China
Christine Pirker Austria
Min Xiao China
Hemant K. Bid India
Dimcho Bachvarov Canada
Jinliang Yang China
Jinyun Liu United States
Roberta Alfieri Italy
Anna Laurenzana Italy
Judy R. van Beijnum Netherlands
Yingqi Zhang relative to Jingxuan Pan China Jingxuan Pan's profile →
Citations per field
00.5×4.5×
Jingxuan Pan · 1×
Citations per year

Countries citing papers authored by Yingqi Zhang

Since Specialization
Citations

This map shows the geographic impact of Yingqi Zhang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yingqi Zhang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yingqi Zhang more than expected).

Fields of papers citing papers by Yingqi Zhang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yingqi Zhang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yingqi Zhang. The network helps show where Yingqi Zhang may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Yingqi Zhang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Yingqi Zhang Line = papers co-authored together Yingqi Zhang links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20252
2 20250
3 20250
4 202415
5 20242
6 202378
7 20228
8 202212
9 20186
10 201810
11 20179
12 201551
13 201412
14 201111
15 20119
16 201019
17 20095
18
Effects of Pueraria Flavonid on Expression of Transferrin Receptor in Quadriceps of Exercise-training Rats
20081
19 200745
20 20065

About Yingqi Zhang

Yingqi Zhang is a scholar working on Immunology, Cancer Research and Oncology, having authored 127 papers that have together received 2.8k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (20 papers), Immunotherapy and Immune Responses (18 papers), Peptidase Inhibition and Analysis (9 papers), Cancer-related molecular mechanisms research (8 papers), Glycosylation and Glycoproteins Research (7 papers), MicroRNA in disease regulation (7 papers), Extracellular vesicles in disease (7 papers) and Immune Response and Inflammation (7 papers). The work is most often cited by research in Cancer Research (482 citations), Immunology (425 citations) and Molecular Biology (1.3k citations). Yingqi Zhang has collaborated with scholars based in China, United States and Australia. Frequent co-authors include Qiang Hao, Long‐Wu Ye, Cun Zhang, Wangqian Zhang, Weina Li, Xiaochang Xue, Shuning Wang, Meng Li, Long Li and Wei Zhang. Their work appears in journals such as Nature, Nucleic Acids Research and Nature Communications.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026